Nextcure to present clinical data from nc318 phase 1/2 clinical trial at 34th annual meeting of sitc

Nextcure, inc. announced that clinical data from the phase 1 portion of its ongoing phase 1/2 clinical trial of nc318 in patients with advanced or metastatic solid tumors will be presented in an oral session at the 34th annual meeting of the society for immunotherapy of cancer (sitc) being held november 6-10, 2019 in national harbor, maryland. nc318 is a first-in-class immunomedicine against siglec-15 (s15), a novel immunomodulatory target found on highly immunosuppressive cells called m2 macrophages in the tumor microenvironment and on certain tumor types including lung, ovarian and head and neck cancers. in preclinical research, it was observed that s15 promoted the survival and differentiation of suppressive myeloid cells and negatively regulated t cell function, allowing cancer to avoid immune destruction. in preclinical studies, nc318 blocked the negative effects of s15. nextcure believes nc318 has the potential to treat multiple cancer types.
NXTC Ratings Summary
NXTC Quant Ranking